Partnership will integrate ICON's clinical trial technology with Advarra's purpose-built system for research sites, embedded across a broad, deeply established global network. Partnership ...
ICON PLC faces a critical test Monday when the contract research organization finally releases long-delayed fourth-quarter ...
Orbis Investment Management released its Q4 2025 investor letter for “Orbis SICAV International Equity Fund”. The Strategy reported a positive year in 2025, with returns driven more by stock-specific ...
ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, ...
Icon PLC (ICLR) came out with quarterly earnings of $2.63 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.90 per share a year ago. These figures are adjusted for ...
Baron Funds, an investment management company, released its “Baron Small Cap Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter of 2025, the ...
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will ...
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at info@ktmc.com. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, ...
SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Investors in ICON plc (ICLR) saw the price of their shares drop about 49% during trading on February 12, 2026, after the company disclosed its ...
DUBLIN--(BUSINESS WIRE)-- ICON plc (ICLR) (NASDAQ: ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results